|
1
|
McGlynn KA, Petrick JL and London WT:
Global epidemiology of hepatocellular carcinoma: An emphasis on
demographic and regional variability. Clin Liver Dis. 19:223–238.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shin JW and Chung YH: Molecular targeted
therapy for hepatocellular carcinoma: Current and future. World J
Gastroenterol. 19:6144–6155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Balogh J, Victor D III, Asham EH,
Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM and Monsour
HP Jr: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma.
3:41–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Colagrande S, Inghilesi AL, Aburas S,
Taliani GG, Nardi C and Marra F: Challenges of advanced
hepatocellular carcinoma. World J Gastroenterol. 22:7645–7659.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barranco SC, Haenelt BR and Gee EL:
Differential sensitivities of five rat hepatoma cell lines to
anticancer drugs. Cancer Res. 38:656–660. 1978.PubMed/NCBI
|
|
7
|
Ferroudj S, Yildiz G, Bouras M, Iscan E,
Ekin U and Ozturk M: Role of fanconi anemia/BRCA pathway genes in
hepatocellular carcinoma chemoresistance. Hepatol Res.
46:1264–1274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chacko S and Samanta S: Hepatocellular
carcinoma: A life-threatening disease. Biomed Pharmacother.
84:1679–1688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Montella L, Palmieri G, Addeo R and Del
Prete S: Hepatocellular carcinoma: Will novel targeted drugs really
impact the next future? World J Gastroenterol. 22:6114–6126. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Villanueva A, Hernandez-Gea V and Llovet
JM: Medical therapies for hepatocellular carcinoma: A critical view
of the evidence. Nat Rev Gastroenterol Hepatol. 10:34–42. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:(Database Issue).
D991–D995. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang W, Soares J, Greninger P, Edelman EJ,
Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et
al: Genomics of Drug sensitivity in cancer (GDSC): A resource for
therapeutic biomarker discovery in cancer cells. Nucleic Acids Res.
41:(Database Issue). D955–D961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Forbes SA, Beare D, Gunasekaran P, Leung
K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et
al: COSMIC: Exploring the world's knowledge of somatic mutations in
human cancer. Nucleic Acids Res. 43:(Database Issue). D805–D811.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Hoo MJ, Imoto S, Nolan J and Miyano S:
Open source clustering software. Bioinformatics. 20:1453–1454.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saldanha AJ: Java Treeview-extensible
visualization of microarray data. Bioinformatics. 20:3246–3248.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liberzon A, Subramanian A, Pinchback R,
Thorvaldsdóttir H, Tamayo P and Mesirov JP: Molecular signatures
database (MSigDB) 3.0. Bioinformatics. 27:1739–6140. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Simon R, Lam A, Li MC, Ngan M, Menenzes S
and Zhao Y: Analysis of gene expression data using BRB-ArrayTools.
Cancer Inform. 3:11–17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kutmon M, van Iersel MP, Bohler A, Kelder
T, Nunes N, Pico AR and Evelo CT: PathVisio 3: An extendable
pathway analysis toolbox. PLoS Comput Biol. 11:e10040852015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kutmon M, Riutta A, Nunes N, Hanspers K,
Willighagen EL, Bohler A, Mélius J, Waagmeester A, Sinha SR, Miller
R, et al: WikiPathways: Capturing the full diversity of pathway
knowledge. Nucleic Acids Res. 44:D488–D494. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kamburov A, Stelzl U, Lehrach H and Herwig
R: The ConsensusPathDB interaction database: 2013 update. Nucleic
Acids Res. 41:(Database Issue). D793–D800. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen C and Wang G: Mechanisms of
hepatocellular carcinoma and challenges and opportunities for
molecular targeted therapy. World J Hepatol. 7:1964–1970. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kojiro M: Histopathology of liver cancers.
Best Pract Res Clin Gastroenterol. 19:39–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lachenmayer A, Alsinet C, Chang CY and
Llovet JM: Molecular approaches to treatment of hepatocellular
carcinoma. Dig Liver Dis. 42 Suppl 3:S264–S272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou Q, Lui VW and Yeo W: Targeting the
PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol.
7:1149–1167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sieghart W, Fuereder T, Schmid K, Cejka D,
Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S,
Peck-Radosavljevic M and Wacheck V: Mammalian target of rapamycin
pathway activity in hepatocellular carcinomas of patients
undergoing liver transplantation. Transplantation. 83:425–432.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Villanueva A, Chiang DY, Newell P, Peix J,
Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, et al:
Pivotal role of mTOR signaling in hepatocellular carcinoma.
Gastroenterology. 135:1972–1983. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huynh H: Molecularly targeted therapy in
hepatocellular carcinoma. Biochem Pharmacol. 80:550–560. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wysocki PJ: Targeted therapy of
hepatocellular cancer. Expert Opin Investig Drugs. 19:265–274.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dibble CC and Cantley LC: Regulation of
mTORC1 by PI3K signaling. Trends Cell Biol. 25:545–55. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vanhaesebroeck B, Stephens L and Hawkins
P: PI3K signalling: The path to discovery and understanding. Nat
Rev Mol Cell Biol. 13:195–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Molina-Cerrillo J, Alonso-Gordoa T, Gajate
P and Grande E: Bruton's tyrosine kinase (BTK) as a promising
target in solid tumors. Cancer Treat Rev. 58:41–50. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Borisa AC and Bhatt HG: A comprehensive
review on Aurora kinase: Small molecule inhibitors and clinical
trial studies. Eur J Med Chem. 140:1–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Damodaran AP, Vaufrey L, Gavard O and
Prigent C: Aurora a kinase is a priority pharmaceutical target for
the treatment of cancers. Trends Pharmacol Sci. 38:687–700. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu F, Wang G, Wang X, Che Z, Dong W, Guo
X, Wang Z, Chen P, Hou D, Zhang Q, et al: Targeting high Aurora
kinases expression as an innovative therapy for hepatocellular
carcinoma. Oncotarget. 8:27953–27965. 2017.PubMed/NCBI
|
|
43
|
Lai CH, Tseng JT, Lee YC, Chen YJ, Lee JC,
Lin BW, Huang TC, Liu YW, Leu TH, Liu YW, et al: Translational
up-regulation of Aurora-A in EGFR-overexpressed cancer. J Cell Mol
Med. 14:1520–1531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen BP, Chan DW, Kobayashi J, Burma S,
Asaithamby A, Morotomi-Yano K, Botvinick E, Qin J and Chen DJ: Cell
cycle dependence of DNA-dependent protein kinase phosphorylation in
response to DNA double strand breaks. J Biol Chem. 280:14709–14715.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Falck J, Coates J and Jackson SP:
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of
DNA damage. Nature. 434:605–611. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yajima H, Lee KJ, Zhang S, Kobayashi J and
Chen BP: DNA double-strand break formation upon UV-induced
replication stress activates ATM and DNA-PKcs kinases. J Mol Biol.
385:800–810. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Weterings E and Chen DJ: The endless tale
of non-homologous end-joining. Cell Res. 18:114–124. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hsu FM, Zhang S and Chen BP: Role of
DNA-dependent protein kinase catalytic subunit in cancer
development and treatment. Transl Cancer Res. 1:22–34.
2012.PubMed/NCBI
|
|
49
|
Munck JM, Batey MA, Zhao Y, Jenkins H,
Richardson CJ, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L,
et al: Chemosensitization of cancer cells by KU-0060648, a dual
inhibitor of DNA-PK and PI-3K. Mol Cancer Ther. 11:1789–1798. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen MB, Zhou ZT, Yang L, Wei MX, Tang M,
Ruan TY, Xu JY, Zhou XZ, Chen G and Lu PH: KU-0060648 inhibits
hepatocellular carcinoma cells through DNA-PKcs-dependent and
DNA-PKcs-independent mechanisms. Oncotarget. 7:17047–17059.
2016.PubMed/NCBI
|
|
51
|
Evert M, Frau M, Tomasi ML, Latte G,
Simile MM, Seddaiu MA, Zimmerman A, Ladu S, Stansca T, Brozzetti S,
et al: Deregulation of DNA-dependent protein kinase catalytic
subunit contributes to human hepatocarcinogenesis development and
has a putative prognostic value. Br J Cancer. 109:2654–2664. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cornell L, Munck JM, Alsinet C, Villanueva
A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt
AD, et al: DNA-PK-A candidate driver of hepatocarcinogenesis and
tissue biomarker that predicts response to treatment and survival.
Clin Cancer Res. 21:925–933. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tu Y, Ji C, Yang B, Yang Z, Gu H, Lu CC,
Wang R, Su ZL, Chen B, Sun WL, et al: DNA-dependent protein kinase
catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet
B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survival.
Mol Cancer. 12:1722013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li Y, Wang X, Yue P, Tao H, Ramalingam SS,
Owonikoko TK, Deng X, Wang Y, Fu H, Khuri FR and Sun SY: Protein
phosphatase 2A and DNA-dependent protein kinase are involved in
mediating rapamycin-induced Akt phosphorylation. J Biol Chem.
288:13215–13224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shi JL, Fu L and Wang WD: High expression
of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel
biomarker for worse prognosis in cytogenetically normal acute
myeloid leukemia. Oncotarget. 6:5299–5309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang F, Wen Y, Guo X, Zhang Y, Wang X,
Yang T, Shen H, Chen X, Tian Q and Deng HW: Genome-wide association
study identifies ITPR2 as a susceptibility gene for Kashin-Beck
disease in Han Chinese. Arthritis Rheumatol. 67:176–181. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wiel C, Lallet-Daher H, Gitenay D, Gras B,
Le Calvé B, Augert A, Ferrand M, Prevarskaya N, Simonnet H,
Vindrieux D and Bernard D: Endoplasmic reticulum calcium release
through ITPR2 channels leads to mitochondrial calcium accumulation
and senescence. Nat Commun. 5:37922014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yildiz G, Arslan-Ergul A, Bagislar S, Konu
O, Yuzugullu H, Gursoy-Yuzugullu O, Ozturk N, Ozen C, Ozdag H,
Erdal E, et al: Genome-wide transcriptional reorganization
associated with senescence-to-immortality switch during human
hepatocellular carcinogenesis. PLoS One. 8:e640162013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Thoresen SB, Pedersen NM, Liestøl K and
Stenmark H: A phosphatidylinositol 3-kinase class III sub-complex
containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates
cytokinesis and degradative endocytic traffic. Exp Cell Res.
316:3368–3378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kristensen L, Kristensen T, Abildgaard N,
Thomassen M, Frederiksen M, Mouritis-Andersen T and Møller MB: High
expression of PI3K core complex genes is associated with poor
prognosis in chronic lymphocytic leukemia. Leuk Res. 39:555–560.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Alberobello AT, Wang Y, Beerkens FJ,
Conforti F, McCutcheon JN, Rao G, Raffeld M, Liu J, Rahhal R, Zhang
YW and Giaccone G: PI3K as a potential therapeutic target in thymic
epithelial tumors. J Thorac Oncol. 11:1345–1356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shull AY, Latham-Schwark A, Ramasamy P,
Leskoske K, Oroian D, Birtwistle MR and Buckhaults PJ: Novel
somatic mutations to PI3K pathway genes in metastatic melanoma.
PLoS One. 7:e433692012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Huang J, Zhang L, Greshock J, Colligon TA,
Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, et al:
Frequent genetic abnormalities of the PI3K/AKT pathway in primary
ovarian cancer predict patient outcome. Genes Chromosomes Cancer.
50:606–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zheng YS, Zhang JY and Zhang DH:
Fatsioside A-induced apoptotic death of HepG2 cells requires
activation of AMP-activated protein kinase. Mol Med Rep.
12:5679–5684. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ishijima N, Kanki K, Shimizu H and Shiota
G: Activation of AMP-activated protein kinase by retinoic acid
sensitizes hepatocellular carcinoma cells to apoptosis induced by
sorafenib. Cancer Sci. 106:567–575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yie Y, Zhao S, Tang Q, Zheng F, Wu J, Yang
L, Deng S and Hann SS: Ursolic acid inhibited growth of
hepatocellular carcinoma HepG2 cells through AMPKα-mediated
reduction of DNA methyltransferase 1. Mol Cell Biochem. 402:63–74.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang H, Li N, Wu J, Su L, Chen X, Lin B
and Luo H: Galangin inhibits proliferation of HepG2 cells by
activating AMPK via increasing the AMP/TAN ratio in a
LKB1-independent manner. Eur J Pharmacol. 718:235–244. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Xieraili M, Yasen M, Mogushi K, Obulhasim
G, Mayinuer A, Aihara A, Tanaka S, Mizushima H, Tanaka H and Arii
S: Villin 1 is a predictive factor for the recurrence of high serum
alpha-fetoprotein-associated hepatocellular carcinoma after
hepatectomy. Cancer Sci. 103:1493–1501. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Buta C, Benabou E, Lequoy M, Régnault H,
Wendum D, Meratbene F, Chettouh H, Aoudjehane L, Conti F, Chrétien
Y, et al: Heregulin-1ß and HER3 in hepatocellular carcinoma: Status
and regulation by insulin. J Exp Clin Cancer Res. 35:1262016.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hsieh SY, He JR, Yu MC, Lee WC, Chen TC,
Lo SJ, Bera R, Sung CM and Chiu CT: Secreted ERBB3 isoforms are
serum markers for early hepatoma in patients with chronic hepatitis
and cirrhosis. J Proteome Res. 10:4715–4724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Gray KA, Yates B, Seal RL, Wright MW and
Bruford EA: Genenames.org: The HGNC resources in 2015. Nucleic
Acids Res. 43:(Database Issue). D1079–D1085. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hay R, Park JG and Gazdar A: Atlas of
human tumor cell lines. Academic Press Inc.; California: pp.
185–212. 1994
|
|
73
|
Yuzugullu H, Benhaj K, Ozturk N, Senturk
S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, et
al: Canonical Wnt signaling is antagonized by noncanonical Wnt5a in
hepatocellular carcinoma cells. Mol Cancer. 8:902009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cevik D, Yildiz G and Ozturk M: Common
telomerase reverse transcriptase promoter mutations in
hepatocellular carcinomas from different geographical locations.
World J Gastroenterol. 21:311–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhao H, Desai V, Wang J, Epstein DM,
Miglarese M and Buck E: Epithelial-mesenchymal transition predicts
sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in
hepatocellular carcinoma cell lines. Mol Cancer Ther. 11:503–513.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Nozaki I, Tsuji T, Sakaguchi M, Inoue Y,
Hirai R, Andou A, Miyazaki M, Shimizu N and Namba M: Establishment
of a human hepatoma cell line, HLE/2E1, suitable for detection of
p450 2E1-related cytotoxicity. In Vitro Cell Dev Biol Anim.
36:566–570. 2000. View Article : Google Scholar : PubMed/NCBI
|
